RxDoctor Payments Data

Kalappurackal Joseph, MD

Psychiatry · Livonia, MINPI 1922195999

Payments from drug & device makers

$1,243in general payments, 2019–2025

Across 42 payments — averaging $29.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$366
  • Johnson & Johnson$311
  • Axsome Therapeutics, Inc.$292
  • Sunovion Pharmaceuticals Inc.$74
  • Lundbeck LLC$61
  • Neurocrine Biosciences, Inc.$33
  • plus $106 from 7 others

What the payments were for

  • Food & beverage$1,21398%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,243 in reported general payments places this provider in the 80th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan

Medicare billing

Part B allowed, 2024
$636,026
Medicare patients
311
Services billed
2,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl131$234,004
CaplytaLumateperone Tosylate50$85,172
RexultiBrexpiprazole40$56,599
SpravatoEsketamine Hcl19$42,167
Invega SustennaPaliperidone Palmitate14$32,554
LybalviOlanzapine/Samidorphan Malate18$26,567
TrintellixVortioxetine Hydrobromide46$24,584
Vilazodone Hcl91$13,994
Desvenlafaxine Succinate ErDesvenlafaxine Succinate212$13,250
Clozapine150$9,542
Quetiapine Fumarate461$9,050
Divalproex Sodium ErDivalproex Sodium120$8,979
Lurasidone Hcl55$8,916
Bupropion XlBupropion Hcl288$8,738
Aripiprazole257$8,363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Viibryd$366$237,886143 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$23$85,17250 claims
Johnson & JohnsonSpravato, Invega Sustenna$311$74,72133 claims
Alkermes, Inc.Lybalvi$22$26,56718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,166 psychiatry providers in Michigan.

Other psychiatry in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →